

**Alabama Department of Public Health (ADPH)
Alabama Emergency Response Technology (ALERT)
Health Alert Network (HAN)
January 11, 2024**

Recommendations for the use of the RSV (respiratory syncytial virus) vaccine in pregnant patients.

In September 2023, the American Council for Immunization Practice (ACIP), the Centers for Disease Control and Prevention (CDC) and the American College of Obstetrics and Gynecology (ACOG) all recommended RSVpreF vaccine using seasonal administration (i.e., during September through end of January in most of the continental United States) for pregnant patients as a one-time dose at 32 weeks and 0 days of gestation through 36 weeks and 6 days of gestation for prevention of RSV lower respiratory tract infection (LRTI) in infants. Of note, the only RSV vaccine approved for use during pregnancy is Pfizer's bivalent RSVpreF vaccine, Abrysvo. GlaxoSmithKline's (GSK) RSVpreF vaccine, Arexvy, is not approved for use in pregnancy.

Although either maternal RSVpreF vaccination during pregnancy or the monoclonal antibody nirsevimab (Beyfortus) administration to the infant after birth each carry recommendations to prevent RSV-associated LRTI, both are not needed for most infants. For the 2023–2024 RSV season, there is a limited supply of the monoclonal antibody for newborns. Therefore, vaccination during pregnancy should be encouraged, particularly in areas where the monoclonal antibody is limited or unavailable. This is the case in many areas of Alabama.

According to CDC and ACOG, the maternal RSV vaccine can be administered at the same time as other vaccines routinely recommended during pregnancy. Clinicians should document receipt or declination of maternal RSV vaccination in the patient's medical chart for communication with other care providers. Pregnant patients who receive the RSV vaccine during pregnancy should be encouraged to participate in v-safe, CDC's vaccine safety monitoring system.

Alabama Medicaid has released information that Abrysvo is a covered service under procedure code 90678. Please see the alert linked below for rate and other details.

For more information, please visit:

<https://www.cdc.gov/mmwr/volumes/72/wr/mm7241e1.htm>

<https://www.cdc.gov/vaccines/vpd/rsv/hcp/pregnant-people.html>

<https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2023/09/maternal-respiratory-syncytial-virus-vaccination>

<https://www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/v-safe/index.html>

https://medicaid.alabama.gov/alert_detail.aspx?ID=16288